Immunic (IMUX) Change in Cash (2013 - 2026)

Immunic has disclosed Change in Cash across 14 years of filings, most recently posting $171.1 million for Q1 2026.

• Change in Cash for Q1 2026 came in at $171.1 million, up 901.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.3 million (up 307.6% YoY), and the FY2025 annual result was -$20.2 million, down 83.4% from the prior year.
• Change in Cash came in at $171.1 million for Q1 2026 at Immunic, up from -$19.6 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $171.1 million in Q1 2026 to a low of -$23.4 million in Q4 2024.
• The 5-year median for Change in Cash is -$15.3 million (2022), against an average of $5.9 million.
• Across the five-year window, Change in Cash tumbled 258.06% in 2023 and soared 901.1% in 2026, its largest moves.
• Immunic's Change in Cash stood at $34.0 million in 2022, then sank by 138.31% to -$13.0 million in 2023, then plunged by 79.82% to -$23.4 million in 2024, then grew by 16.04% to -$19.6 million in 2025, then jumped by 971.02% to $171.1 million in 2026.
• The last three Change in Cash figures came in at $171.1 million (Q1 2026), -$19.6 million (Q4 2025), and -$20.2 million (Q3 2025), per Business Quant data.